Artiva Biotherapeutics (ARTV) Enterprise Value (2023 - 2025)
Artiva Biotherapeutics (ARTV) has disclosed Enterprise Value for 3 consecutive years, with -$108.0 million as the latest value for Q4 2025.
- Quarterly Enterprise Value rose 41.75% to -$108.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$108.0 million through Dec 2025, up 41.75% year-over-year, with the annual reading at -$108.0 million for FY2025, 41.75% up from the prior year.
- Enterprise Value for Q4 2025 was -$108.0 million at Artiva Biotherapeutics, up from -$123.0 million in the prior quarter.
- The five-year high for Enterprise Value was $50.2 million in Q2 2024, with the low at -$301.6 million in Q1 2025.
- Average Enterprise Value over 3 years is -$110.8 million, with a median of -$108.0 million recorded in 2025.
- Peak annual rise in Enterprise Value hit 193.51% in 2024, while the deepest fall reached 1036.69% in 2024.
- Over 3 years, Enterprise Value stood at $19.8 million in 2023, then plummeted by 1036.69% to -$185.4 million in 2024, then surged by 41.75% to -$108.0 million in 2025.
- According to Business Quant data, Enterprise Value over the past three periods came in at -$108.0 million, -$123.0 million, and -$256.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.